MUTATION C3435T IN MULTI-DRUG RESISTANCE GENE MDR1 AS PHARMACOGENETIC MARKER OF SEVERE COURSE OF BRONCHIAL ASTHMA

Background. Early detection and treatment of severe forms of bronchial asthma (BA) is one of serious problems in clinical practice. BA is a multifactorial disease, so its progression is a result of both environmental factors and genetic predisposition. Aim of the study. To determine frequencies of genetic variants resulted from the mutation C3435T (rs1045642) in MDR1 gene among patients with different BA severity and in healthy controls. Methods. The trial included 122 patients with different severity of BA course and 103 healthy controls. Genomic DNA was extracted from peripheral blood leucocytes by routine phenol-chloroform protocol. Allelic variants were determined by polymerase chain reaction with subsequent restriction analysis with MboI restriction endonuclease. Results. For the first time association of allelic variant 3435C of MDR1 gene with BA was revealed. Differences between MDR1 genotypes distributions persisted in case of stratification BA patients according their severity courses. Severity of BA course was found to be strongly associated with 3435C allele. Conclusion. Allele 3435C and genotype 3435CC of gene MDR1 are markers of increased risk of BA progression. In patients with BA these alleles are associated with unfavorable severe course of the disease. Genotype 3435TT of gene MDR1 is a protective marker associated with favorable and well-controlled BA course.

pharmacogenetics, MDR1 gene, P-glycoprotein 170, bronchial asthma, glucocorticosteroids